Analysts have set 12-month price targets for BioNTech, revealing an average target of $132.24, a high estimate of $171.00, ...
in.investing.com on MSN5h
Denmark shares lower at close of trade; OMX Copenhagen 20 down 0.14%Denmark equities were lower at the close on Thursday, as losses in the Copenhagen Real Estate, OMX Copenhagen Personal & Household Goods PI and Copenhagen Health Care sectors led shares lower. At the ...
Denmark stocks were lower after the close on Thursday, as losses in the Real Estate, Personal & Household Goods and ...
Assetmark Inc. boosted its stake in shares of Genmab A/S (NASDAQ:GMAB – Free Report) by 16.2% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 82,629 shares of ...
Deutsche Bank lowered the firm’s price target on Genmab (GMAB) to DKK 2,250 from DKK 2,500 and keeps a Buy rating on the shares.
Genmab A/S logged a -1.6% change during today's morning session, and is now trading at a price of $22.1 per share. The S&P ...
Collaboration Revenue - Collaboration revenue was $1.1 million for the quarter ended September 30, 2024, compared to $2.5 ...
The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...
GEN1047, GEN3017, and GEN1056—to refocus resources, following its recent $1.8 billion acquisition of ProfoundBio. The move ...
TD Cowen analyst Yaron Werber has maintained their neutral stance on GMAB stock, giving a Hold rating yesterday. Yaron Werber has given his ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback